Clinical Trials Logo

Lung Non-Small Cell Carcinoma clinical trials

View clinical trials related to Lung Non-Small Cell Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05740501 Completed - Melanoma Clinical Trials

Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer

Start date: April 26, 2017
Phase:
Study type: Observational

This early phase I study collects blood samples and monitors the levels of pembrolizumab and nivolumab as they move through the body in patients with melanoma and/or non-small cell lung cancer. Pembrolizumab and nivolumab are a monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Studying samples of blood in the laboratory from patients receiving pembrolizumab and nivolumab may help doctors learn more about the effects of pembrolizumab and nivolumab on cells. It may also help doctors understand how well patients respond to treatment. Information from this study may be used in the future to guide physicians to make dosage adjustments based on serum concentrations of drug to minimize adverse side effects and maximize the effect of the drug.

NCT ID: NCT05304793 Completed - Clinical trials for Lung Non-Small Cell Carcinoma

Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

This trial studies the effect of a form of cognitive-behavioral therapy, Take a Breath, on reducing the intensity and frequency of dyspnea (difficulty breathing) in patients with lung cancer. Take a Breath consists of individual therapy sessions that educate patients on dyspnea and provides coping strategies.

NCT ID: NCT03944265 Completed - Clinical trials for Stage IV Lung Cancer AJCC v8

Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

Start date: February 8, 2019
Phase: N/A
Study type: Interventional

This trial studies the use of genetics and shared decision making in improving care for patients with stage IVA-C non-small cell lung cancer. Developing educational tools may help patients with non-small cell lung cancer to increase patient treatment knowledge, reduce decisional conflict, and promote treatment shared decision making with their health care providers.